Isolation and Optimization of Murine IL-10 Receptor Blocking Oligonucleotide Aptamers Using High-throughput Sequencing.

Interleukin-10 (IL-10) is a key suppressor of inflammation in chronic infections and in cancer. In mice, the inability of the immune system to clear viral infections or inhibit tumor growth can be reversed by antibody-mediated blockade of IL-10 action. We used a modified selection protocol to isolate RNA-based, nuclease-resistant, aptamers that bind to the murine IL-10 receptor. After 5 rounds of selection high-throughput sequencing (HTS) was used to analyze the library. Using distribution statistics on about 11 million sequences, aptamers were identified which bound to IL-10 receptor in solution with low Kd. After 12 rounds of selection the predominant IL-10 receptor-binding aptamer identified in the earlier rounds remained, whereas other high-affinity aptamers were not detected. Prevalence of certain nucleotide (nt) substitutions in the sequence of a high-affinity aptamer present in round 5 was used to deduce its secondary structure and guide the truncation of the aptamer resulting in a shortened 48-nt long aptamer with increased affinity. The aptamer also bound to IL-10 receptor on the cell surface and blocked IL-10 function in vitro. Systemic administration of the truncated aptamer was capable of inhibiting tumor growth in mice to an extent comparable to that of an anti- IL-10 receptor antibody.

[1]  W. Haining,et al.  Resolution of a chronic viral infection after interleukin-10 receptor blockade , 2006, The Journal of experimental medicine.

[2]  J. McNamara,et al.  Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. , 2011, Nucleic acid therapeutics.

[3]  B. Sullenger,et al.  Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. , 2007, Oligonucleotides.

[4]  G. Trinchieri,et al.  Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor Antibody , 2002, The Journal of experimental medicine.

[5]  E John Wherry,et al.  T cell exhaustion , 2011 .

[6]  M Yarus,et al.  Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.

[7]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[8]  Youjin Lee,et al.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors , 2005, The Journal of experimental medicine.

[9]  W. Thilly,et al.  Fidelity of DNA polymerases in DNA amplification. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Lohman,et al.  A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Pawlotsky,et al.  Improved dendritic cell‐based immunization against hepatitis C virus using peptide inhibitors of interleukin 10 , 2011, Hepatology.

[12]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[13]  D. Accapezzato,et al.  Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection , 2004 .

[14]  D. Pardoll,et al.  Cancer immunotherapy: breaking the barriers to harvest the crop , 2004, Nature Medicine.

[15]  H. Jessen,et al.  IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. , 2009, Blood.

[16]  G. Trinchieri,et al.  Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. , 2005, Cancer research.

[17]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[18]  J. McNamara,et al.  Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. , 2008, The Journal of clinical investigation.

[19]  E. Rigopoulou,et al.  Blocking of interleukin-10 receptor--a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. , 2005, Clinical immunology.

[20]  E. Wherry,et al.  IL-10, T cell exhaustion and viral persistence. , 2007, Trends in microbiology.

[21]  Seung Soo Oh,et al.  Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing , 2010, Proceedings of the National Academy of Sciences.

[22]  T. Mosmann,et al.  Interleukin 10: a novel stimulatory factor for mast cells and their progenitors , 1991, The Journal of experimental medicine.

[23]  E. Riley,et al.  IL-10: The Master Regulator of Immunity to Infection , 2008, The Journal of Immunology.

[24]  L. Teyton,et al.  Interleukin-10 determines viral clearance or persistence in vivo , 2006, Nature Medicine.

[25]  D. McGavern,et al.  IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection , 2008, The Journal of experimental medicine.